Table 2.
Examples of ongoing clinical trials involving EV-based therapies
| Disease | EV Source | EV Modification | Phase, Cohort | NIH Clinical Trial Identifier |
|---|---|---|---|---|
| Acute ischemic stroke | Mesenchymal stromal cells (MSCs) | Enriched with miR-124 | Phase 1/2, N = 5 | NCT03384433 |
| Bronchopulmonary dysplasia | MSCs | Not specified | Phase 1, N = 18 | NCT03857841 |
| Colon cancer | Plant | Loaded with curcumin | Phase 1, N = 35 | NCT01294072 |
| Malignant ascites and pleural effusion | Tumor-derived | Loaded with chemotherapeutic drugs | Phase 2, N = 30 | NCT01854866 |
| Malignant pleural effusion | Malignant pleural effusion | Loaded with methotrexate | Phase 2, N = 90 | NCT02657460 |
| Metastatic pancreatic cancer | MSCs | KrasG12D siRNA | Phase 1, N = 28 | NCT03608631 |
| Macular holes (MHs) | MSCs | Not specified | Phase 1, N = 44 | NCT03437759 |
| Radiation and chemotherapy-induced oral mucositis | Grape-derived | Unmodified | Phase 1, N = 60 | NCT01668849 |
| Ulcers | Plasma | Unmodified | Phase 1, N = 5 | NCT02565264 |